Blood typing and transfusion therapy in a patient with A2 subtype acute myeloid leukemia M2:A case report

BACKGROUND Acute myeloid leukemia(AML)is one of the most common types of leukemia in adults.However,AML is relatively rare in the population overall,accounting for only about 1 percent of all cancers.Treatment for AML can be very effective for some patients,yet it leaves others with serious and even life-threatening side effects.Chemotherapy is still the primary treatment for most AML,but over time,leukemia cells become resistant to chemotherapy drugs.In addition,stem cell transplantation,targeted therapy,and immunotherapy are currently available.At the same time,with the progression of the disease,the patient may have corresponding complications,such as coagulation dysfunction,anemia,granulocytopenia,and repeated infection,so transfusion supportive therapy will be involved in the overall treatment regime.To date,few articles have reported on blood transfusion treatment options for patients with ABO subtypes AML-M2.Blood transfusion therapy is an important supportive treatment for AML-M2,and accurate determination of patients'blood type is one of the most important steps in the treatment process.In this study,we explored blood typing and supportive treatment strategies for a patient with A2 subtype AML-M2 to provide the basis for treatment for all patients.CASE SUMMARY In order to determine the blood type of the patient,serological and molecular biological methods were used for reference tests,and the genetic background was studied to determine the patient's final blood type and select the appropriate blood products for infusion treatment.According to the results obtained by serological and molecular biological methods,the blood type of the patient was A2 subtype;the genotype was A02/001;the irregular antibody screening was negative,and anti-A1 was found in the plasma.According to the overall treatment plan,active anti-infection,elevated cells,component blood transfusion support,and other rescue and supportive treatments were given,and the patient successfully passed the stage of myelosuppression after chemotherapy.Re-examination of bone marrow smears showed that AL was in complete remission of bone marrow signs,and minimal residual leukemia lesions suggested no cells with obvious abnormal immunophenotype(residual leukemia cells<10-4).CONCLUSION The infusion of patients with A2 subtype AML-M2 with A irradiated platelets and O washing red blood cells can meet the needs of clinical treatment.

Emergency Biosafety Management Practice in Laboratory of Shelter Hospital

At the end of 2019,the novel coronavirus infection outbroke in Wuhan,Hubei Province.On Feb.2,2020,Wuhan,as the worst-hit region,began to build“shelter hospital”rapidly to treat patients with mild ilness.The shelter hospital has multiple functions such as emergency treatment,surgical treatment and clinical test,which can adapt to emergency medical rescue tasks.Based on the characteristics that shelter hospital only treats patients with mild ilness,tests of shelter laboratory,including coronavirus nucleic acid detection,IgM/IgG antibody serology detection,monitoring and auxiliary diagnosis and/or a required blood routine,urine routine,C-reactive protein,calcitonin original,biochemical indicators(liver enzymes,myocardial enzymes,renal function,etc.)and blood coagulation function test etc,were used to provide important basis for the diagnosis and treatment of the disease.In order to ensure laboratory biosafety,it is necessary to first evaluate the harm level of various specimens.In the laboratory biosafety management,the harm level assessment of microorganisms is the core work of biosafety,which is of great significance to guarantee biosafety.As an emergency deployment afcted by the environment,shelter laboratory must possess strong mobility.This paper will explore how to combine the biosafety model of traditional laboratory with the particularity of shelter laboratory to carry out effective work in response to the current epidemic.